Study identification

PURI

https://redirect.ema.europa.eu/resource/27563

EU PAS number

EUPAS8840

Study ID

27563

Official title and acronym

Dose response curves for patients prescribed small & large particle ICS formulation: an observational evaluation of the comparative effect of ICS dose on asthma control achieved in real-life UK patients managed on extrafine hydrofluoroalkane beclomethasone, ciclesonide, fluticasone propionate, or Clenil

DARWIN EU® study

No

Study countries

United Kingdom

Study description

Aims to evaluate the relationship between ICS dose and treatment outcomes for patients prescribed small or large particle formulation by comparing asthma control outcomes associated with different doses of each ICS in order to create real-life dose-response curves.The outcomes evaluated are change in severe exacerbation rates, change in percent predicted PEF and change in average daily SABA dose

Study status

Finalised
Research institution and networks

Institutions

Contact details

David Price

Primary lead investigator
Study timelines

Date when funding contract was signed

Actual:

Study start date

Actual:

Date of final study report

Actual:
Sources of funding
Pharmaceutical company and other private sector 

More details on funding

Teva
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable